表观遗传学
基因
生物
染色质
组蛋白
遗传学
细胞分化
基因表达调控
调节器
细胞命运测定
溴尿嘧啶
髓系白血病
表型
细胞生物学
癌症研究
转录因子
作者
Fangxue Yan,Jinyang Li,Jelena Milosevic,Ricardo Petroni,Suying Liu,Zhennan Shi,Salina Yuan,Janice Reynaga,Yuwei Qi,Joshua Rico,Sixiang Yu,Yiman Liu,Susumu Rokudai,Neil Palmisiano,Sara E. Meyer,Pamela J. Sung,Liling Wan,Fei Lan,Benjamin A. Garcia,Ben Z. Stanger,David B. Sykes,Andres Blanco
出处
期刊:Cancer Discovery
[American Association for Cancer Research]
日期:2022-03-01
卷期号:12 (3): 792-811
被引量:22
标识
DOI:10.1158/2159-8290.cd-20-1459
摘要
Epigenetic programs are dysregulated in acute myeloid leukemia (AML) and help enforce an oncogenic state of differentiation arrest. To identify key epigenetic regulators of AML cell fate, we performed a differentiation-focused CRISPR screen in AML cells. This screen identified the histone acetyltransferase KAT6A as a novel regulator of myeloid differentiation that drives critical leukemogenic gene-expression programs. We show that KAT6A is the initiator of a newly described transcriptional control module in which KAT6A-catalyzed promoter H3K9ac is bound by the acetyl-lysine reader ENL, which in turn cooperates with a network of chromatin factors to induce transcriptional elongation. Inhibition of KAT6A has strong anti-AML phenotypes in vitro and in vivo, suggesting that KAT6A small-molecule inhibitors could be of high therapeutic interest for mono-therapy or combinatorial differentiation-based treatment of AML.AML is a poor-prognosis disease characterized by differentiation blockade. Through a cell-fate CRISPR screen, we identified KAT6A as a novel regulator of AML cell differentiation. Mechanistically, KAT6A cooperates with ENL in a "writer-reader" epigenetic transcriptional control module. These results uncover a new epigenetic dependency and therapeutic opportunity in AML. This article is highlighted in the In This Issue feature, p. 587.
科研通智能强力驱动
Strongly Powered by AbleSci AI